Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dauricine SCHEMBL22089144 | 1.00 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Dauricine SCHEMBL29494083 | 1.00 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Dauricine SCHEMBL28689430 | 1.00 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Dauricine SCHEMBL29494084 | 1.00 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Dauricine SCHEMBL2233953 | 1.00 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Daruisoline SCHEMBL24212114 | 0.97 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| Daruisoline SCHEMBL31192245 | 0.97 | KCNH2 (1.00) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| SCHEMBL29411700 | 0.97 | KCNH2 (0.96) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| SCHEMBL21125616 | 0.95 | KCNH2 (0.90) | KCNH2BCHEACHEKDM4EALDH1A1 | |
| SCHEMBL28672292 | 0.95 | KCNH2 (0.90) | KCNH2BCHEACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023487-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2013-01-24 | — | — | US | disclosed |
| US-8067401-B2 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2011-11-29 | — | — | US | disclosed |
| US-20090069277-A1 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LTD. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023487-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION | RPN2, LSS, CLIC4 | KCNH2 984/4885BCHE 985/4885ACHE 1234/4885 |
| US-20090069277-A1 | Compounds and compositions for treating infection | RPN2, LSS, CLIC4 | KCNH2 984/4885BCHE 985/4885ACHE 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.